Does Cyp3a Inhibitors Moderate And Strong Interact with Tovorafenib?
Cyp3a Inhibitors Moderate And Strong and Tovorafenib have a moderate drug interaction according to U.S. FDA drug labeling data. CYP2C8 inhibitors are predicted to increase tovorafenib exposure, which may increase the risk of adverse reactions. Avoid coadministration. The mechanism involves tovorafenib is a cyp2c8 substrate; inhibitors increase its exposure. Patients taking both medications should consult their healthcare provider before starting, stopping, or changing the dosage of either drug. This information is based on official FDA drug labeling sourced from OpenFDA and the NIH National Library of Medicine.
- Severity
- Moderate
- Tovorafenib Class
- Kinase Inhibitor
- Management
- Monitor for effects
- Data Source
- U.S. FDA via OpenFDA
How This Interaction Works
The interaction between Cyp3a Inhibitors Moderate And Strong and Tovorafenib occurs because tovorafenib is a cyp2c8 substrate; inhibitors increase its exposure. Clinically, this means cyp2c8 inhibitors are predicted to increase tovorafenib exposure, which may increase the risk of adverse reactions. avoid coadministration. This is classified as a moderate interaction. While it may not require stopping either medication, your healthcare provider should be aware you are taking both so they can monitor for potential effects and adjust treatment if necessary.
What To Tell Your Doctor or Pharmacist
If you are taking Cyp3a Inhibitors Moderate And Strong and your doctor is considering prescribing Tovorafenib (or vice versa), make sure to:
- Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
- Ask whether the benefits of combining these medications outweigh the risks for your specific situation
- Ask what symptoms to watch for that would indicate the interaction is causing problems
- Ask whether any dosage adjustments are needed
- Never stop or change either medication without first consulting your healthcare provider